Primary endpoint: Disease-free survival (DFS) in patients with Stage II to IIIA NSCLC1
Secondary endpoints: DFS in overall population, DFS at 2, 3, and 5 years, overall survival, safety, health-related quality of life1,3
References: 1. Wu Y-L, Tsuboi M, He J, et al; ADAURA Investigators. Osimertinib in resected EGFR-mutated non–small-cell lung cancer. N Engl J Med. 2020. doi:10.1056/NEJMoa2027071. 2. AstraZeneca Pharmaceuticals. TAGRISSO® (osimertinib). Summary of Product Characteristics, 2021. 3. AstraZeneca. AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. (ADAURA). Available from: https://www.clinicaltrials.gov/ct2/show/NCT02511106. NLM identifier: NCT02511106. Accessed March 8, 2021.